Billion dollar buy could open door to growing RSV market

12 December 2023
vaccine_shot_jab_booster_big

Continuing a busy period of dealmaking, pharma major AstraZeneca (LSE: AZN) has confirmed it will buy vaccine specialist Icosavax (Nasdaq: ICVX) for around $800 million.

In recent weeks, Britain’s largest drugmaker has announced a new  AI-based collaboration, a  cell therapy partnership in China, the launch of a  digital health company and the  acquisition of rights to a novel KRAS blocker.

The latest deal will see the company augment its newly-established vaccines experience with the integration of an American biotech focused on an innovative, protein virus-like particle (VLP) platform.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical